 |
|
|
| |
Telaprevir, Peginterferon and Ribavirin Combination Therapy for Chronic HCV Genotype 1 in HCV/HIV Co-infected Patients: Early Response and Viral Resistance
|
| |
| |
Reported by Jules Levin
CROI 2013 March 3-6 Atlanta
Kenneth E. Sherman,1 Doug J. Bartels,2 Mohammad Bsharat,2 Raymond A. Rubin,2 Tara L. Kieffer,2 Mark S. Sulkowski3
1University of Cincinnati College of Medicine, Cincinnati, OH, USA; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 3Johns Hopkins University School of Medicine, Baltimore, MD, USA
|
| |
|
|
|
|
|
